Authors' objectives: To evaluate the efficacy and safety of the addition of bevacizumab to standard chemotherapy in patients with advanced ovarian cancer.

Authors' recommendations: The addition of bevacizumab to standard chemotherapy in patients with advanced ovarian cancer showed no survival benefit in the overall study population. However, high-risk patients with a poor prognosis achieved a benefit in OS, although it has to be considered that the increase is based on data of the ICON7 trial using an unlicensed dose of bevacizumab. Furthermore, the improvements in PFS are not statistically significant. Hence, high additional costs and increased AEs stand in contrast to modest efficacy improvements. However, the impact of any prolongation of the patient's life might be relevant, even if the addition of bevacizumab is not associated with an improved quality of life. Since the ICON7 trial was conducted with an unlicensed dose of bevacizumab, it is difficult to assess the applicability of the results and, not least, their impact on the treatment costs.

Project Status: Completed

URL for project: http://eprints.hta.lbg.ac.at/1082/

Year Published: 2016

URL for published report: http://eprints.hta.lbg.ac.at/1082/1/DSD_HSO_Nr.56.pdf

URL for additional information: http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Austria

Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment

Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99

Contact Name: tarquin.mittermayr@aihta.at

Contact Email: office@aihta.at

Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)